Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 5
Treatment-assignment count: 0
Stratification count: 0
Drug Development Ahead Of Cdx Context
ALK fusion
gastric cancer · Monoclonal Antibody
ALK fusion is flagged as drug development ahead of cdx context because public trials show inclusion required evidence in 5 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 4
Common snippets: dMMR | dMMR | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT05113459 | https://clinicaltrials.gov/study/NCT02678182 | https://clinicaltrials.gov/study/NCT04744649 | https://clinicaltrials.gov/study/NCT05468138 | https://clinicaltrials.gov/study/NCT04006821